Argus initiates 10X Genomics stock coverage with buy on Atera demand

Argus initiated 10X Genomics (TXG) at Buy with a $110 target, citing demand for its new Atera spatial-biology platform; Q2 2026 Atera orders exceeded the company’s target of delivering 40 systems for the full year. Q2 revenue of $151.04 million beat the $146.64 million consensus, while adjusted EPS loss of $0.14 was narrower than the expected $0.24 loss. Shares have surged 631% over the past year to near a 52-week high of $86.16, but investors remain cautious over Atera-related cannibalization, softer near-term outlook, and potentially elevated valuation.

Analysis

TXG’s valuation now depends less on incremental instrument placements than on whether the installed base converts into a high-frequency consumables stream. The key underwriting variable over the next 1-3 quarters is revenue per deployed Atera unit and the pace at which legacy spatial revenue migrates without creating a purchase pause; a strong launch can still be earnings-dilutive if manufacturing yield, service costs, and field-support spending scale faster than consumables pull-through. The sharp equity appreciation leaves little tolerance for a merely successful rollout.

Competitive pressure should shift from legacy single-cell tools toward spatial-biology workflow economics. BRKR, through its spatial portfolio, and ILMN through the sequencing ecosystem are the most plausible indirect beneficiaries if the category expands; however, TXG wins disproportionately only if its workflow reduces total sample-to-insight time enough to make customers standardize on its consumables. Drug-discovery AI is a longer-duration narrative rather than a near-term revenue driver: biopharma customers need reproducible datasets and validated biology before materially expanding budgets.

The contrarian view is that capacity-constrained demand is not equivalent to durable end-market demand. Early orders may reflect launch-cycle procurement, grant timing, and competitive evaluation rather than repeatable utilization, while cannibalization can obscure organic growth in the mature franchise. A downside rerating would likely begin with any reduction in unit-delivery cadence, weaker consumables attach, or gross-margin pressure during the production ramp; conversely, two consecutive quarters of above-plan placements plus stable gross margin would justify a higher multiple.

Key Decisions for Investors

• Do not chase TXG at highs before the next earnings update; establish a watch trigger for disclosed Atera placements, backlog conversion, consumables revenue per instrument, and gross-margin trajectory. Upgrade to a 3-6 month long only if placements exceed plan without a material deterioration in legacy consumables growth.
• For existing TXG longs, retain core exposure but hedge the launch-execution window with 3-6 month put spreads, sized to protect against a 20-30% de-rating. The hedge is justified because the primary risk is multiple compression rather than a modest quarterly revenue miss.
• Consider a small tactical TXG/BRKR relative-value long/short only after verifying comparable spatial-revenue exposure and valuation inputs: long TXG if Atera utilization is demonstrated, short BRKR if its spatial growth fails to accelerate. Use a 1-3 month horizon and exit if TXG reports weak consumables pull-through or BRKR shows stronger-than-expected spatial order growth.
• Treat AI-enabled drug discovery as a 6-18 month optionality catalyst, not a basis for near-term estimates. Reassess the long thesis if management cannot quantify biopharma adoption, repeat purchase behavior, or a path to operating leverage by the next two reporting periods.